| Sayed, Christopher J |
| Recruiting | 2 | 15 | US | Anifrolumab, anifrolumab-fnia, Saphnelo | University of North Carolina, Chapel Hill, AstraZeneca | Hidradenitis Suppurativa, Acne Inversa, Hidradenitis | 06/26 | 12/26 | | |
NCT05194969: Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery |
|
|
| Completed | N/A | 74 | US | Wet-to-Dry Dressings, Petrolatum with Non-Stick Gauze | University of North Carolina, Chapel Hill | Hidradenitis Suppurativa, Surgical Wound | 10/23 | 10/23 | | |
| Hanami, Erika |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
NCT06158113: Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study |
|
|
| Recruiting | 2 | 10 | US | Baricitinib 4 milligram Oral Tablet, Olumiant | University of North Carolina, Chapel Hill, Eli Lilly and Company | Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus | 03/25 | 03/25 | | |
| Recruiting | 2 | 15 | US | Anifrolumab, anifrolumab-fnia, Saphnelo | University of North Carolina, Chapel Hill, AstraZeneca | Hidradenitis Suppurativa, Acne Inversa, Hidradenitis | 06/26 | 12/26 | | |
| Lugo-Somolinos, Aida |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
| Culton, Donna Aline |
NCT06158113: Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study |
|
|
| Recruiting | 2 | 10 | US | Baricitinib 4 milligram Oral Tablet, Olumiant | University of North Carolina, Chapel Hill, Eli Lilly and Company | Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus | 03/25 | 03/25 | | |
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) |
|
|
| Recruiting | 1 | 55 | US | DSG3-CAART or CABA-201 | Cabaletta Bio | Pemphigus Vulgaris | 01/29 | 01/29 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
